Actinogen Halted as It Reviews XanaMIA Alzheimer’s Trial Results
ACW: $0.045 +0.00% · MC: $182M
Actinogen Medical’s shares have been placed in a trading halt while the company reviews and analyses results from its XanaMIA Phase 2b/3 Alzheimer’s trial. The halt is expected to last until a material announcement or no later than Tuesday, 17 November.

Comments